FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  REARDON WILLIAM S					IDE	2. Issuer Name and Ticker or Trading Symbol IDERA PHARMACEUTICALS, INC. [ IDRA ]									k all appli Directo	ationship of Reportin all applicable) Director Officer (give title below)		10% Ov	wner
• • • • • • • • • • • • • • • • • • • •					3. Date of Earliest Transaction (Month/Day/Year) 06/07/2017										Other (s below)			pecity	
167 SIDNEY STREET					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	LIDGE M	Α (	02139											X		iled by One iled by More า		Ū	
(City)	(S	tate) (	Zip)																
		Tab	le I - No	on-Deriv	ative S	Sec	urities	Ac	quired, [	Disp	osed o	f, or Be	nefic	cially	Owne	t			
1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day)						Execution Date,			3. Transaction Code (Instr. 8)  4. Securities Acquired Disposed Of (D) (Instr. and 5)					3, 4 Securit Benefic Owned		ies Fo		Direct (	7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	(A) (D)	or Pi	rice	Followi Reporte Transac (Instr. 3	ed etion(s)	(Instr. 4)		(Instr. 4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		on of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)				9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	, [C	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
					Code	v	(A)		Date Exercisable		xpiration ate	Title	or Num of Shar	ber					
Stock Options <sup>(1)</sup>	\$1.63	06/07/2017			Α		50,000		06/07/2018 <sup>(2</sup>	2) 0	6/07/2027	Common Stock	50,0	000	\$0	50,000		D	

## **Explanation of Responses:**

- 1. These options were granted pursuant to the Company's director compensation on the date of the Company's 2017 annual meeting of stockholders at an exercise price to the closing price of the Company's common stock on the date of grant.
- 2. These options will vest in full and become immediately exercisable on the first anniversary of the date of grant, subject to continued service as director, and are granted under the Company's 2013 Stock Incentive Plan, as amended.

/s/ William S Reardon 06/08/2017

Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.